Protocols

Lilly to display drug pricing info on website; Catalent pledges $200M for its biologics unit

→ Since the bipartisan bill compelling pharmaceutical companies to display drug prices as part of their television advertisements was torpedoed in September, the biopharma drug pricing controversy has only intensified. Eli Lilly $LLY, which announced an $8 billion bet on Loxo Oncology $LLY on Monday, has set up a page (https://www.lillypricinginfo.com/) on its website so patients can look up the prices carried by its drugs. According to Bloomberg, which first reported the news, Lilly will air television ads brandishing the page in tandem with a toll-free helpline.

Biopharma contract drug developer and manufacturer Catalent $CTLT, which bought out Juniper Pharmaceuticals last year to beef up its early drug development offerings in the UK, is planning to invest $200 million in its biologics business over three years at its manufacturing sites in Madison, Wisconsin and Bloomington, Indiana, it said on Monday.

Weeks after initiating a Phase III study for experimental bladder cancer therapy, Israel-based Anchiano Therapeutics — formerly known as BioCanCell — has filed for an IPO worth up to $35 million. No pricing terms were disclosed.

Gene therapy developer Apic Bio, which was spun out of the University of Massachusetts Medical School, scored $40 million in a Series A round led by Morningside Venture Investments. The company has also hired Scott Loiler, who formerly worked with Nationwide Children’s Hospital, as CTO.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 37,400+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biotech Investment Analyst
SV Health Investors Boston, MA
Director, Program Management
Contrafect Corporation New York, NY
Director, Translational Sciences
Cadent Therapeutics Cambridge, MA

Visit Endpoints Careers ->